Sun Pharmaceutical Industry a well-known drug maker company announced the launch of a new medicine in United States market named Ilumya which is a plaque psoriasis treatment medicine on Tuesday. The Ilumya drug is capable of treating moderate to severe range of psoriasis and holds up strength up to 100 mg. Abhay Gandhi CEO of the Sun Pharma North America stated that making Ilumya available in the United States is a major step for them as it will help the company grow in the US as well. This medicine will be a relief to people who were still looking out for ways by which they can manage their moderate to severe range of plaque psoriasis. The CEO exclaimed that they are well aware about the needs of the patients as well as the physician and thus the company was and is committed to make Ilumya more reasonable and effective amongst the many drugs sold in the market. The company is working hard to increase the distribution among the market and reach to each and every patient who requires help for plaque psoriasis. The shares of the Sun Pharmaceutical Industry were settled at 576.30 rupees for each scrip on the BSE, which is less by 5.o7 percent from the last close.